Authors: Advani, R Fisher, GA Lum, BL Hausdorff, J Halsey, J Litchman, M Sikic, BI

Citation: R. Advani et al., A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance, CLIN CANC R, 7(5), 2001, pp. 1221-1229

Authors: Visani, G Milligan, D Leoni, F Chang, J Kelsey, S Marcus, R Powles, R Schey, S Covelli, A Isidori, A Litchman, M Piccaluga, PP Mayer, H Malagola, M Pfister, C

Citation: G. Visani et al., Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia, LEUKEMIA, 15(5), 2001, pp. 764-771

Authors: Dorr, R Karanes, C Spier, C Grogan, T Greer, J Moore, J Weinberger, B Schiller, G Pearce, T Litchman, M Dalton, W Roe, D List, AF

Citation: R. Dorr et al., Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia, J CL ONCOL, 19(6), 2001, pp. 1589-1599

Authors: Fracasso, PM Westerveldt, P Fears, CA Rosen, DM Zuhowski, EG Cazenave, LA Litchman, M Egorin, MJ

Citation: Pm. Fracasso et al., Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (valspodar), in refractory malignancies, J CL ONCOL, 18(5), 2000, pp. 1124-1134

Authors: Patnaik, A Warner, E Michael, M Egorin, MJ Moore, MJ Siu, LL Fracasso, PM Rivkin, S Kerr, I Litchman, M Oza, AM

Citation: A. Patnaik et al., Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors, J CL ONCOL, 18(21), 2000, pp. 3677-3689

Authors: Advani, R Saba, HI Tallman, MS Rowe, JM Wiernik, PH Ramek, J Dugan, K Lum, B Villena, J Davis, E Paietta, E Litchman, M Sikic, BI Greenberg, PL

Citation: R. Advani et al., Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC833 (Valspodar), BLOOD, 93(3), 1999, pp. 787-795